FDA Approves Ensartinib for ALK-positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer By Ogkologos - February 6, 2025 224 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the eXALT3 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR Nivolumab Plus Low-Dose Ipilimumab Demonstrates Clinical Benefit in First-Line Treatment for... October 20, 2021 Drug Combination Shows Promise for Rhabdomyosarcoma, but Can It Get to... December 9, 2022 Experts Propose a Clinical Definition of Acquired Resistance to PD-(L)1 Blockade... September 7, 2021 Resource Round-Up: Let’s Win Pancreatic Cancer May 23, 2023 Load more HOT NEWS FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma Sodium Thiosulfate Approved to Reduce Chemo-Related Hearing Loss in Children with... Breaking News: Supreme Court Upholds the Affordable Care Act Acing it: The ambitious early career researchers driving progress in cancer...
